Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Adjuvant Colon Cancer w/ ELOXatin®/5 FU Based Regimen: ACCELOX

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier:
NCT01310972
First received: March 6, 2011
Last updated: February 24, 2016
Last verified: December 2011
  Purpose
Adjuvant Colon Cancer With ELOXatin®/5 FU Based Regimen: ACCELOX

Condition Intervention
Colon Cancer
Other: Registry

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Adjuvant Colon Cancer With ELOXatin®/5 FU Based Regimen: ACCELOX

Resource links provided by NLM:


Further study details as provided by King Faisal Specialist Hospital & Research Center:

Primary Outcome Measures:
  • OS, PFS, DFS [ Time Frame: For the duration of the experiment ] [ Designated as safety issue: Yes ]

Enrollment: 6
Study Start Date: September 2007
Study Completion Date: September 2007
Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Other: Registry
    Registry
Detailed Description:
It's a study of adjuvant colon carcinoma using ELOXatin/5-FU based chemotherapeutic regimen called ACCELOX as a definitive curative therapy.
  Eligibility

Ages Eligible for Study:   14 Years to 85 Years   (Child, Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Colon Cancer Registry
Criteria

Inclusion Criteria:

  • Patients with Adjuvant Colon Cancer

Exclusion Criteria:

  • Patients with diagnosis other than Colon Cancer.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01310972

Locations
Saudi Arabia
Kfsh & Rc
Riyadh, Saudi Arabia
Sponsors and Collaborators
King Faisal Specialist Hospital & Research Center
Investigators
Principal Investigator: Al Jubran, M.D. KFSH & RC
  More Information

Responsible Party: King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier: NCT01310972     History of Changes
Other Study ID Numbers: RAC# 2071-027  RAC# 2071-027 
Study First Received: March 6, 2011
Last Updated: February 24, 2016
Health Authority: United States: Institutional Review Board
Individual Participant Data  
Plan to Share IPD: Undecided

Keywords provided by King Faisal Specialist Hospital & Research Center:
Adjuvant Colon Cancer

Additional relevant MeSH terms:
Colonic Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Oxaliplatin
Antineoplastic Agents

ClinicalTrials.gov processed this record on September 29, 2016